NOVAVAX INC Operating Cash Flow
NOVAVAX INC (NVAX) reported Operating Cash Flow of -$105.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- NOVAVAX INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$72.81M.
- NOVAVAX INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$32.42M.
- NOVAVAX INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$39.48M.
- NOVAVAX INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $107.80M.
- NOVAVAX INC net cash provided by (used in) operating activities for fiscal 2025 was -$244.63M.
- NOVAVAX INC net cash provided by (used in) operating activities for fiscal 2024 was -$87.26M.
- NOVAVAX INC net cash provided by (used in) operating activities for fiscal 2023 was -$713.97M.
- NOVAVAX INC net cash provided by (used in) operating activities for fiscal 2022 was -$415.94M, a 228.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$72.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$105.23M 10-Q · filed 2026-08-06 | -$144.71M derived: sum of 3 quarters · filed 2026-08-06 | -$36.90M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$32.42M 10-Q · filed 2026-05-06 | -$71.90M derived: sum of 2 quarters · filed 2026-05-06 | $35.91M derived: sum of 3 quarters · filed 2026-05-06 | -$91.56M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$39.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.33M derived: sum of 2 quarters · filed 2026-02-26 | -$59.13M derived: sum of 3 quarters · filed 2026-08-06 | -$244.63M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $107.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$19.66M derived: sum of 2 quarters · filed 2026-08-06 | -$205.16M 10-Q · filed 2025-11-06 | -$378.32M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$127.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$312.96M 10-Q · filed 2026-08-06 | -$486.13M derived: sum of 3 quarters · filed 2026-08-06 | -$630.94M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$185.50M 10-Q · filed 2026-05-06 | -$358.67M derived: sum of 2 quarters · filed 2026-05-06 | -$503.48M derived: sum of 3 quarters · filed 2026-05-06 | -$189.21M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$173.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$317.98M derived: sum of 2 quarters · filed 2026-02-26 | -$3.71M derived: sum of 3 quarters · filed 2026-02-26 | -$87.26M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | -$144.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $169.46M derived: sum of 2 quarters · filed 2025-11-06 | $85.90M 10-Q · filed 2025-11-06 | -$90.88M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $314.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $230.71M 10-Q · filed 2025-08-06 | $53.93M derived: sum of 3 quarters · filed 2026-02-26 | $14.28M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | -$83.56M 10-Q · filed 2025-05-08 | -$260.34M derived: sum of 2 quarters · filed 2026-02-26 | -$299.99M derived: sum of 3 quarters · filed 2026-02-26 | -$471.93M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | -$176.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$216.44M derived: sum of 2 quarters · filed 2026-02-26 | -$388.37M derived: sum of 3 quarters · filed 2026-02-26 | -$713.97M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$39.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$211.59M derived: sum of 2 quarters · filed 2024-11-12 | -$537.19M 10-Q · filed 2024-11-12 | -$655.00M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$171.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$497.53M 10-Q · filed 2024-08-08 | -$615.35M derived: sum of 3 quarters · filed 2025-02-27 | -$654.05M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$325.59M 10-Q · filed 2024-05-10 | -$443.41M derived: sum of 2 quarters · filed 2025-02-27 | -$482.12M derived: sum of 3 quarters · filed 2025-02-27 | -$653.02M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$117.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$156.52M derived: sum of 2 quarters · filed 2025-02-27 | -$327.43M derived: sum of 3 quarters · filed 2025-02-27 | -$415.94M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$38.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$209.61M derived: sum of 2 quarters · filed 2023-11-09 | -$298.12M 10-Q · filed 2023-11-09 | -$640.53M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | -$170.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$259.41M 10-Q · filed 2023-08-08 | -$601.82M derived: sum of 3 quarters · filed 2024-02-28 | -$743.96M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | -$88.51M 10-Q · filed 2023-05-09 | -$430.92M derived: sum of 2 quarters · filed 2024-02-28 | -$573.06M derived: sum of 3 quarters · filed 2024-02-28 | -$428.65M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | -$342.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$484.55M derived: sum of 2 quarters · filed 2024-02-28 | -$340.14M derived: sum of 3 quarters · filed 2024-02-28 | $322.95M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$142.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.27M derived: sum of 2 quarters · filed 2022-11-09 | $665.35M 10-Q · filed 2022-11-09 | $536.79M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | $144.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $807.50M 10-Q · filed 2022-08-09 | $678.93M derived: sum of 3 quarters · filed 2023-02-28 | $672.43M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $663.09M 10-Q · filed 2022-05-10 | $534.52M derived: sum of 2 quarters · filed 2023-02-28 | $528.02M derived: sum of 3 quarters · filed 2023-02-28 | $643.65M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$128.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$135.06M derived: sum of 2 quarters · filed 2023-02-28 | -$19.43M derived: sum of 3 quarters · filed 2023-02-28 | -$42.54M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $109.14M derived: sum of 2 quarters · filed 2021-11-05 | $86.03M 10-Q · filed 2021-11-05 | $62.28M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $115.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $92.52M 10-Q · filed 2021-08-05 | $68.78M derived: sum of 3 quarters · filed 2022-03-01 | $36.52M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | -$23.11M 10-Q · filed 2021-05-10 | -$46.85M derived: sum of 2 quarters · filed 2022-03-01 | -$79.11M derived: sum of 3 quarters · filed 2022-03-01 | -$109.13M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$23.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$56.00M derived: sum of 2 quarters · filed 2022-03-01 | -$86.02M derived: sum of 3 quarters · filed 2022-03-01 | -$136.62M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$32.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$62.27M derived: sum of 2 quarters · filed 2020-11-10 | -$112.88M 10-Q · filed 2020-11-10 | -$158.15M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | -$30.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$80.62M 10-Q · filed 2020-08-10 | -$125.89M derived: sum of 3 quarters · filed 2021-03-01 | -$159.40M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | -$50.61M 10-Q · filed 2020-05-11 | -$95.87M derived: sum of 2 quarters · filed 2021-03-01 | -$129.39M derived: sum of 3 quarters · filed 2021-03-01 | -$169.36M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$45.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$78.78M derived: sum of 2 quarters · filed 2021-03-01 | -$118.75M derived: sum of 3 quarters · filed 2021-03-01 | -$184.82M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | -$33.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$73.48M derived: sum of 2 quarters · filed 2019-11-07 | -$139.56M 10-Q · filed 2019-11-07 | -$182.96M derived: sum of 4 quarters · filed 2020-03-11 | ||
| 2018-06-30 | -$39.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$106.05M 10-Q · filed 2019-08-07 | -$149.44M derived: sum of 3 quarters · filed 2020-03-11 | -$193.62M derived: sum of 4 quarters · filed 2020-03-11 | ||
| 2018-03-31 | -$66.08M 10-Q · filed 2019-05-02 | -$109.47M derived: sum of 2 quarters · filed 2020-03-11 | -$153.65M derived: sum of 3 quarters · filed 2020-03-11 | -$166.05M derived: sum of 4 quarters · filed 2020-03-11 | ||
| 2017-12-31 | -$43.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$87.58M derived: sum of 2 quarters · filed 2020-03-11 | -$99.98M derived: sum of 3 quarters · filed 2020-03-11 | -$144.48M 10-K · filed 2020-03-11 | -$138.70M 10-K · filed 2018-03-14 | |
| 2017-09-30 | -$44.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$56.58M derived: sum of 2 quarters · filed 2018-11-07 | -$101.08M 10-Q · filed 2018-11-07 | -$106.62M 10-Q · filed 2017-11-07 | -$165.63M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-06-30 | -$12.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$56.90M 10-Q · filed 2018-08-08 | -$121.45M derived: sum of 3 quarters · filed 2019-03-18 | |||
| 2017-03-31 | -$44.50M 10-Q · filed 2018-05-09 | -$109.05M derived: sum of 2 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | -$64.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$258.77M 10-K · filed 2019-03-18 | -$255.47M 10-K · filed 2018-03-14 | |||
| 2016-09-30 | -$194.22M 10-Q · filed 2017-11-07 | |||||
| 2015-12-31 | -$126.09M 10-K · filed 2018-03-14 | |||||
| 2014-03-31 | -$20.43M 10-Q · filed 2014-05-08 | |||||
| 2013-09-30 | -$14.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$22.51M derived: sum of 2 quarters · filed 2013-11-12 | -$33.10M 10-Q · filed 2013-11-12 | -$36.35M derived: sum of 4 quarters · filed 2014-05-08 | ||
| 2013-06-30 | -$7.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$18.22M 10-Q · filed 2013-08-08 | -$21.47M derived: sum of 3 quarters · filed 2014-05-08 | -$26.10M derived: sum of 4 quarters · filed 2014-05-08 | ||
| 2013-03-31 | -$10.58M 10-Q · filed 2014-05-08 | -$13.84M derived: sum of 2 quarters · filed 2014-05-08 | -$18.47M derived: sum of 3 quarters · filed 2014-05-08 | -$24.59M derived: sum of 4 quarters · filed 2014-05-08 | ||
| 2012-12-31 | -$3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$7.88M derived: sum of 2 quarters · filed 2013-11-12 | -$14.01M derived: sum of 3 quarters · filed 2013-11-12 | -$18.23M 10-K · filed 2013-03-12 | ||
| 2012-09-30 | -$4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$10.76M derived: sum of 2 quarters · filed 2013-11-12 | -$14.98M 10-Q · filed 2013-11-12 | -$14.14M 10-Q · filed 2012-11-09 | -$17.85M derived: sum of 4 quarters · filed 2013-11-12 | |
| 2012-06-30 | -$6.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$10.35M 10-Q · filed 2013-08-08 | -$13.21M derived: sum of 3 quarters · filed 2013-08-08 | -$16.54M derived: sum of 4 quarters · filed 2013-08-08 | ||
| 2012-03-31 | -$4.22M 10-Q · filed 2013-05-09 | -$7.09M derived: sum of 2 quarters · filed 2013-05-09 | -$10.41M derived: sum of 3 quarters · filed 2013-05-09 | -$18.81M derived: sum of 4 quarters · filed 2013-05-09 | ||
| 2011-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$6.19M derived: sum of 2 quarters · filed 2013-03-12 | -$14.59M derived: sum of 3 quarters · filed 2013-03-12 | -$23.63M 10-K · filed 2013-03-12 | ||
| 2011-09-30 | -$3.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$11.72M derived: sum of 2 quarters · filed 2012-11-09 | -$20.76M 10-Q · filed 2012-11-09 | -$26.57M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-06-30 | -$8.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$17.44M 10-Q · filed 2012-08-09 | -$23.25M derived: sum of 3 quarters · filed 2013-03-12 | -$31.56M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-03-31 | -$9.04M 10-Q · filed 2012-05-09 | -$14.85M derived: sum of 2 quarters · filed 2013-03-12 | -$23.17M derived: sum of 3 quarters · filed 2013-03-12 | |||
| 2010-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$14.13M derived: sum of 2 quarters · filed 2013-03-12 | -$32.85M 10-K · filed 2013-03-12 | |||
| 2010-09-30 | -$8.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | -$27.04M 10-Q · filed 2011-11-08 | ||||
| 2010-06-30 | -$18.73M 10-Q · filed 2011-08-09 | |||||
| 2009-12-31 | -$32.83M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |